Novavax (NASDAQ: NVAX) revenue
Novavax reported revenue of $1,123m for fiscal 2025, 64.7% more than in fiscal 2024 ($682.2m). Since fiscal 2016 its revenue has grown by 7,217.7%, an average growth of 61.1% a year.
Novavax's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2023, −50.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,123m | +64.7% | $452.8m | 40.3% |
| 2024 | $682.2m | −30.7% | −$248.9m | −36.5% |
| 2023 | $983.7m | −50.4% | −$566.5m | −57.6% |
| 2022 | $1,982m | +72.9% | −$644.7m | −32.5% |
| 2021 | $1,146m | +141.0% | −$1,687m | −147.1% |
| 2020 | $475.6m | +2,448.5% | −$416.7m | −87.6% |
| 2019 | $18.7m | −45.6% | −$120.6m | −646.1% |
| 2018 | $34.3m | +10.0% | −$173.9m | −507.2% |
| 2017 | $31.2m | +103.1% | −$171.7m | −550.8% |
| 2016 | $15.4m | — | −$269.1m | −1,752.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Novavax revenue compared with its sector
By revenue for its latest fiscal year, Novavax ranks 143rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Novavax, 64.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 141st | Trulieve Cannabis | $1,181m | −0.4% |
| 142nd | Sotera Health | $1,164m | 5.7% |
| 143rd | Novavax | $1,123m | 64.7% |
| 144th | Waystar | $1,099m | 16.5% |
| 145th | Prestige Consumer Healthcare | $1,089m | −4.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Novavax
- How much revenue did Novavax make in fiscal 2025?
- Novavax reported revenue of $1,123m for fiscal 2025, compared with $682.2m in fiscal 2024.
- How much has the revenue of Novavax grown?
- Between fiscal 2016 and fiscal 2025 it went from $15.4m to $1,123m: 7,217.7% more, an average growth of 61.1% a year.
- What was the best year for revenue at Novavax?
- Of its last 10 fiscal years, fiscal 2022, with $1,982m.
- Where does Novavax rank in its sector by revenue?
- It ranks 143rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Novavax come from?
- From the annual report (Form 10-K) that Novavax files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Novavax files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Novavax: the Novavax page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.